DaVita stock has rallied strongly over the last three years, yet its valuation signals do not fully line up. The Discounted Cash Flow (DCF) intrinsic value estimate points to a premium to current fundamentals, while the market multiple checks appear more supportive.

• DaVita has returned 131.7% over the past three years, which puts extra focus on whether the current price still reflects its long term cash flow potential.
• Future growth in dialysis volumes and cash flow may support the current share price. However, any sustained pressure on reimbursement rates or treatment margins may affect what investors are willing to pay.
• With a valuation score of 3 out of 6, DaVita presents a mixed picture rather than a clear bargain or clear overvaluation on the broader checks.

The issue now is whether DaVita's recent share price strength leaves enough room between market price and intrinsic value estimate to appeal to new investors.

Does DaVita Look Pricey on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what DaVita might be worth based on the cash it is expected to generate for shareholders. For DaVita, the model uses latest twelve month free cash flow of about $1.44b and assumes cash flows ease back from that level over time rather than compound at a rapid growth rate.

Using these inputs, the DCF model indicates an intrinsic value of about $199 per share. Compared with the current share price, this suggests DaVita stock screens around 18.9% overvalued based on current cash flow assumptions and discount rate settings.

On the DCF view, DaVita appears overvalued at today’s share price.

Our Discounted Cash Flow (DCF) analysis suggests DaVita may be overvalued by 18.9%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Does DaVita Look Undervalued on Earnings?

The P/E ratio is a useful way to look at DaVita because it ties the share price directly to the earnings that support it. It helps you judge what the market is currently willing to pay for each dollar of profit.

DaVita trades on a P/E of about 20.1x, which sits below both the Healthcare industry average of 26.1x and the peer average of 41.0x. The fair P/E ratio estimate for DaVita is 26.2x, which is higher than the current market multiple. This gap suggests the stock changes hands at a lower earnings multiple than would typically be expected given its sector, size and risk profile.

If the fair ratio is a reasonable guide, the current P/E leaves room for the earnings multiple to move closer to that reference point over time, subject to how DaVita’s fundamentals develop. This stands in contrast to the DCF output, which indicated a richer valuation on cash flow assumptions.

On the P/E yardstick, DaVita stock appears to trade on a lower multiple relative to both its tailored fair multiple and broader Healthcare peers.

The DaVita Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for DaVita pick up where this valuation puzzle leaves off by spelling out which paths for DaVita's growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price, based on the recent checks. Instead of a single output from a ratio or model, they describe the future those figures rely on so you can monitor whether that story is actually taking shape over time on the Community page.

The community is split on DaVita, with one camp seeing upside from AI driven kidney care and another focused on reimbursement and volume pressure.

Bull case: 12% undervalued

"Ongoing technology and AI investments in clinical platforms, scheduling, call centers and revenue operations are expected to lower administrative friction, support higher collections and structurally expand operating margins and free cash flow…"

Bear case: 22% overvalued

"Annual reimbursement rate updates from CMS (e.g., the 2% ESRD proposed rate) continue to lag actual inflation experienced by dialysis providers, signaling ongoing and future margin compression as government reimbursement rates struggle to keep pace with rising costs, threatening net margins and cash flow…"

Do you think there's more to the story for DaVita? Head over to our Community to see what others are saying!

The Bottom Line

The Discounted Cash Flow (DCF) view suggests DaVita trades at a premium to its intrinsic value, while the P/E comparison points to an undervalued earnings multiple relative to peers. That split reflects different sensitivities. The intrinsic value model leans heavily on cash flow timing and capital needs, while the market multiple view leans on how investors currently rate DaVita's earnings against comparable stocks. With the broader checks sitting in mixed territory, the key consideration is whether margins and reimbursement hold up well enough to support both strong cash generation and any potential change in the earnings multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.